Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine.

Conforte AJ, Tuszynski JA, da Silva FAB, Carels N.

Front Genet. 2019 Oct 21;10:930. doi: 10.3389/fgene.2019.00930. eCollection 2019.

2.

[Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].

Peng S, Li X, Liu Q, Zhang Y, Zou L, Gong X, Wang M, Ma X.

Nan Fang Yi Ke Da Xue Xue Bao. 2019 Jun 30;39(6):641-649. doi: 10.12122/j.issn.1673-4254.2019.06.03. Chinese.

PMID:
31270041
3.

Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy.

Flashner-Abramson E, Vasudevan S, Adejumobi IA, Sonnenblick A, Kravchenko-Balasha N.

Theranostics. 2019 Jul 9;9(18):5149-5165. doi: 10.7150/thno.31657. eCollection 2019.

4.

Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach.

Cheng F, Liu C, Shen B, Zhao Z.

BMC Syst Biol. 2016 Aug 26;10 Suppl 3:65. doi: 10.1186/s12918-016-0309-9.

5.

LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.

Liu B, Chen Y, Yang J.

Oncotarget. 2017 Apr 11;8(15):24275-24291. doi: 10.18632/oncotarget.13651.

6.

Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma.

Li N, Zhao J, Ma Y, Roy B, Liu R, Kristiansen K, Gao Q.

Oncol Lett. 2018 Sep;16(3):3992-4000. doi: 10.3892/ol.2018.9113. Epub 2018 Jul 10.

7.

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells.

Zhang Y, He RQ, Dang YW, Zhang XL, Wang X, Huang SN, Huang WT, Jiang MT, Gan XN, Xie Y, Li P, Luo DZ, Chen G, Gan TQ.

Cancer Cell Int. 2016 Dec 1;16:89. doi: 10.1186/s12935-016-0366-6. eCollection 2016.

8.

Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.

Gan BL, He RQ, Zhang Y, Wei DM, Hu XH, Chen G.

Int J Oncol. 2018 Oct;53(4):1557-1579. doi: 10.3892/ijo.2018.4508. Epub 2018 Jul 30.

9.

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.

Lucchetta M, da Piedade I, Mounir M, Vabistsevits M, Terkelsen T, Papaleo E.

BMC Cancer. 2019 Aug 20;19(1):824. doi: 10.1186/s12885-019-5965-x.

10.
11.

Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation.

Luo J, Shi K, Yin SY, Tang RX, Chen WJ, Huang LZ, Gan TQ, Cai ZW, Chen G.

World J Surg Oncol. 2018 Apr 10;16(1):76. doi: 10.1186/s12957-018-1378-6.

12.

Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.

Yuan L, Bing Z, Yan P, Li R, Wang C, Sun X, Yang J, Shi X, Zhang Y, Yang K.

Gene. 2019 Oct 20;716:144025. doi: 10.1016/j.gene.2019.144025. Epub 2019 Aug 5. Review.

PMID:
31394177
13.

Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.

Yang Y, Wang M, Liu B.

J Cell Physiol. 2019 Apr;234(4):4454-4459. doi: 10.1002/jcp.27240. Epub 2018 Oct 14.

PMID:
30317601
14.

Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.

Sun F, Yang X, Jin Y, Chen L, Wang L, Shi M, Zhan C, Shi Y, Wang Q.

Mol Med Rep. 2017 Jul;16(1):609-616. doi: 10.3892/mmr.2017.6629. Epub 2017 May 25.

15.

High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.

Zhou S, Wang P, Su X, Chen J, Chen H, Yang H, Fang A, Xie L, Yao Y, Yang J.

PLoS One. 2017 Oct 31;12(10):e0187356. doi: 10.1371/journal.pone.0187356. eCollection 2017. Erratum in: PLoS One. 2018 Apr 19;13(4):e0196354.

16.

IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer.

Mounika Inavolu S, Renbarger J, Radovich M, Vasudevaraja V, Kinnebrew GH, Zhang S, Cheng L.

CPT Pharmacometrics Syst Pharmacol. 2017 Mar;6(3):168-176. doi: 10.1002/psp4.12167. Epub 2017 Mar 7. Review.

17.
18.

Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis.

Xie ZC, Li TT, Gan BL, Gao X, Gao L, Chen G, Hu XH.

Pathol Res Pract. 2018 May;214(5):644-654. doi: 10.1016/j.prp.2018.03.028. Epub 2018 Apr 5.

PMID:
29650443
19.

Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.

Zhong K, Yang F, Han Q, Chen J, Wang J.

Oncol Lett. 2018 Sep;16(3):2873-2880. doi: 10.3892/ol.2018.9000. Epub 2018 Jun 20.

20.

GSNFS: Gene subnetwork biomarker identification of lung cancer expression data.

Doungpan N, Engchuan W, Chan JH, Meechai A.

BMC Med Genomics. 2016 Dec 5;9(Suppl 3):70. doi: 10.1186/s12920-016-0231-4.

Supplemental Content

Support Center